Table 1 Baseline characteristics of the included studies.
Author/year | Region | Study name | Design | Sample sizes (% male) | Age (years) | NT-proBNP comparison | Follow-up (years) | No. death/HR (95% CI) | Adjustment for variables | Overall NOS |
|---|---|---|---|---|---|---|---|---|---|---|
Kistorp et al.7 | Denmark | — | Population-based prospective study | 626 (42.3) | 67.9 ± 10.6 | >80th percentile vs. others; >655.4 pg/ml vs. ≤655.4 pg/ml | 5 | Total death:94 1.96 (1.21–3.19) | Age, sex, current smoking, DB, hypertension and ischemic heart disease, TC, and creatinine | 8 |
Laukkanen et al.8 | Finland | KIHD | Prospective study | 905 (100) | 55.8 ± 6.6 | >90th percentile vs. others; >133.4 pmol/L vs. ≤133.4 pmol/L | 9.8 | CV death:58; 2.3 (1.23–4.23); Total death:110; 2.01 (1.23–3.29) | Age, smoking, DB, SBP, family history of CHD, presence or absence of CHD, BMI, LDL, HDL, CRP, creatinine, and antihypertensive drugs. | 7 |
März et al.16 | Germany | LURIC | Prospective study | 506 (NP)^ | 61.1 ± 10.8 | Tertile 3 vs. tertile 1; ≥400 ng/L vs. <100 ng/L | 5.45 | CV death:16 8.93 (0.97–82.28); Total death:32; 1.88 (0.53–6.64) | Age, sex, DB, CRP, BMI, smoking, hypertension, dyslipidemia, eGFR, presence or absence of CAD on angiography, previous MI, use of beta-blockers, ACEIs, ARBs, CCBs, diuretics, antiplatelet drugs, lipid-lowering agents, revascularization at baseline, and LV function | 6 |
Zethelius et al.9 | Sweden | ULSAM | Prospective community-based study | 661 (100) # | 71 ± 0.6 | Cutoff value; >309 ng/liter vs. ≤309 ng/liter | 10.0 | CV death:54 4.69 (2.53–8.72); Total death:149; 2.50 (1.60–3.89) | Age, SBP, use or non use of antihypertensive or lipid- lowering agent, TC, HDL, DB, smoking, and BMI | 8 |
deFilippi et al.10 | USA | CHS | Prospective community-based study | 2,975 (40.6) | 72.7 ± 5.5 | Quintile 5 vs. quintile 1; >267.7 pg/ml vs. <47.5 pg/ml | 11.9 | CV death:539 3.02 (2.36–3.86) | Age, sex, race, smoking, TC, HDL, SBP, hypertension., DB, BMI, CHD, renal function, any major ECG abnormality, use of ACEIs/ARBs, beta-blockers, and diuretics | 7 |
McKie et al.17 | USA | REP | Prospective community-based cohort | 703 (47)* | 56 ± 7 | >80th percentile vs. others; >196 pg/ml for women and >125 pg/ml for men. | 10 | Total death:19 1.06 (0.24–4.74) | Age, sex, and BMI. | 5 |
Doi et al.11 | Japan | Hisayama | Population-based prospective study | 3,104 (42.0) | 61.3 ± 12.4 | Quintile 4 vs. quintile 1; ≥400 pg/ml vs. <55 pg/ml | 5 | CV death:48 12.87 (2.44–67.75) | Age, sex, SBP, electrocardiogram abnormalities, eGFR., BMI, DB, TC, HDL, smoking, alcohol, and regular exercise | 7 |
Wannamethee et al.12 | UK | BRHS | Prospective study | 2,983 (100) | 60–79 | Quintile 4 vs. quintile 1; ≥151 pg/ml vs. ≤40 pg/ml | 9 | CV death:223 2.64 (1.56–4.47); CHD death:119 1.98 (1.01–3.93) | Age, smoking, physical activity, alcohol intake, BMI, SBP, HD, TC, FEV1, DB, CRP, anemia, atrial fibrillation, and eGFR | 8 |
Oluleye et al.13 | USA | ARIC | Prospective cohort study | 11,193 (NP) | 45–64 | Quintile 5 vs. quintile 1; ≥159 pg/ml vs. ≤27.4 pg/ml | 9.9 | CV death:358 5.10 (3.16–8.22); CHD death:138 2.81 (1.41–5.60); Total death:1,909 2.46 (1.98–3.05); | Age, gender, race, BMI, TC, HDL, diet, sport index, smoking, drinking, hormone use, SBP, antihypertensive medication, DB, FEV1, eGFR., Hs-CRP, and troponin T. (total mortality was adjusted for history of cancer, CVD, stroke, HF, and respiratory disease. | 8 |
van Peet et al.14 | The Netherlands | Leiden 85-plus | Prospective cohort study | 560 (34) | ≥ 85 | Tertile 3 vs. tertile 1; >649 pg/ml vs. <201 pg/ml in men and >519 pg/ml vs. <204 pg/ml in women | 5 | CV death:100 5.5 (3.1–10); Total death:258 2.9 (2.1–4.0) | Age, sex, microalbuminuria, eGFR, prevalent CVD, DB, SBP, use of antihypertensive drugs, smoking, BMI, TC, HDL, and lipid medication use. | 6 |
Zhu et al.15 | China | — | Community-based prospective survey | 1,499 (42) | 61.4 ± 11.4 | Quintile 4 vs. quintile 1; ≥81.9 pg/ml vs. <19.8 pg/ml | 4.8 | Total death:52 3.59 (1.22–8.81) | Age, sex, current smoking, BMI, SBP, DBP, FBG, TC, HDL-C, LDL-C, eGFR, high-sensitivity CRP, and homocysteine. | 6 |
